Biogen, Sobi Offer New Data from Phase 3 Trial of ALPROLIX
July 02, 2013 at 11:06 AM EDT
Biogen Idec (NASDAQ: BIIB ) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today presented new findings for their long-lasting recombinant factor IX candidate ALPROLIX^* for hemophilia B at the XXIV International Society on Thrombosis and Haemostasis (ISTH) Congress in Amsterdam, The Netherlands. Three oral presentations showcase new data that reinforce the